Table 3 Potential Nano-DDS for oral delivery to curb Leishmaniasis
From: Nanotechnology based solutions for anti-leishmanial impediments: a detailed insight
Type of Nano-DDS | Nanosystem engineered | Loaded anti-leishmanial drug | Characterization | Leishmanial strain | Animal model | Major results | References |
|---|---|---|---|---|---|---|---|
Nano-dispersions | Nanosuspension | Amphotericin B | In-vitro | – | – | Enhanced Amp-B solubility and dissolution | [151] |
Polymeric-based nanocarriers | PLGA NPs | Amphotericin B | In vitro + In vivo | L. donovani | BALB/c mice | Fabricated NPs comparable to that of injectable liposomal formulation in terms of the liver, spleen, and bone marrow parasitic burden reduction | |
Chitosan NPs | Rifampicin | In vitro | – | – | Biphasic drug release with 90% of drug release in 24 h at least | [156] | |
PEGylated PLGA NPs | Amphotericin B | In vitro | – | – | Drug laden NPs have shown bi-phasic drug release (initial abrupt release followed by slow release) | [157] | |
PLGA NPs | Pentamidine | In vitro + In vivo | L. infantum | BALB/c mice | 0.4 mg/kg (totally 5 doses) of the fabricated NPs are associated with a valuable reduction in hepatomegaly and splenomegaly along with parasitic burden as well | [149] | |
Lipid-based Nanocarrier | HPBC Modified SLNs | Amphotericin-B + Paromomycin | In vitro + In vivo | L. donovani | BALB/c mice | Sustained release of the entrapped drug is observed with significant parasitic burden reduction in BALB/c mice model followed by oral administration Improved macrophage internalization, reduced toxicity, and enhanced anti-leishmanial efficacy | [154] |